Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMC Life Sciences BhdXKLS:0101 60 Forward PE Ratio is 0.00 as of Jul. 23, 2026. GuruFocus rates XKLS:0101 with a GF Score™ of 60/100 and a GF Value™ of RM0.62 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 313 Healthcare Providers & Services companies, TMC Life Sciences Bhd ranks worse than 319488.5% on this metric.
TMC Life Sciences Bhd (XKLS:0101) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
TMC Life Sciences Bhd Forward PE Ratio Related Terms
TMC Life Sciences Bhd Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for TMC Life Sciences Bhd's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMC Life Sciences Bhd Forward PE Ratio Chart
TMC Life Sciences Bhd Annual Data
Trend
Forward PE Ratio
TMC Life Sciences Bhd Quarterly Data
Forward PE Ratio
XKLS:0101 vs HCA, THC, DVA: Forward PE Ratio Comparison
For the Medical Care Facilities subindustry, TMC Life Sciences Bhd's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMC Life Sciences Bhd Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, TMC Life Sciences Bhd's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where TMC Life Sciences Bhd's Forward PE Ratio falls into.
TMC Life Sciences Bhd Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
TMC Life Sciences Bhd (XKLS:0101) has a Forward PE Ratio of 0.00 as of Jul. 23, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on TMC Life Sciences Bhd and its competitors. According to the industry distribution chart, TMC Life Sciences Bhd ranks #999999 out of 313 companies in the Healthcare Providers & Services industry.
Is TMC Life Sciences Bhd's Forward PE Ratio too high?
TMC Life Sciences Bhd's current Forward PE Ratio is 0.00. Based on the distribution chart, TMC Life Sciences Bhd ranks #999999 out of 313 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, TMC Life Sciences Bhd has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TMC Life Sciences Bhd's Forward PE Ratio compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, TMC Life Sciences Bhd ranks #999999 out of 313 companies for Forward PE Ratio. This places TMC Life Sciences Bhd in the lower half of its industry. The industry median Forward PE Ratio is 18.42. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.42, based on 313 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on TMC Life Sciences Bhd and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TMC Life Sciences Bhd's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMC Life Sciences Bhd stock overvalued right now?
Based on GuruFocus' analysis, TMC Life Sciences Bhd (XKLS:0101) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.62, compared to a current price of RM0.47 — trading 24.2% below its estimated fair value. The current Forward PE Ratio is 0.00. TMC Life Sciences Bhd's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For TMC Life Sciences Bhd (XKLS:0101), the current Forward PE Ratio is 0.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TMC Life Sciences Bhd (XKLS:0101) Overvalued in 2026?
Based on GuruFocus' analysis, TMC Life Sciences Bhd stock appears to be undervalued.
The current stock price of RM0.47 is trading 24.2% below its estimated GF Value™ of RM0.62.
GuruFocus considers TMC Life Sciences Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:0101:
Forward PE Ratio: 0.00
GF Value™: RM0.62 vs. price of RM0.47 (24.2% below fair value)
No single metric tells the full story. See the XKLS:0101 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TMC Life Sciences Bhd is an investment holding company operating a multi-disciplinary tertiary care center and fertility center in Malaysia. It operates Tropicana Medical Centre, Kota Damansara (TMCKD), a medical center located in Petaling Jaya. Its TMCKD provides healthcare services in various medical/surgical specialties and subspecialties, including anesthesiology, cancer, cardiology, colorectal, dermatology, ENT, fertility, gastroenterology, as well as offers internal medicines and respiratory medicines. Its fertility center provides a range of fertility treatments for couples. The company also operates a women's clinic; provides fertility consultancy, laboratory, and embryology services; and offers pharmacy services and products.
60GF Score
Get the complete analysis for XKLS:0101
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0101 has been successfully added to your 
